Effects of Different Doses of Aspirin on Pathophysiological Markers in Type 2 Diabetes
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Michael H Cummings, MD, FRCP
Portsmouth Hospitals NHS TRust & University of Portsmouth
Study Director - Rajeev P Raghavan, MBBS, MRCP
Portsmouth Hospitals NHS Trust
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Diabetes Centre, Queen Alexandra Hospital, Portsmouth Hospitals Nhs Trust
Portsmouth, Hampshire, United Kingdom
- School of Pharmacy and Biomedical Sciences, University of Posrtmouth
Portsmouth, Hampshire, United Kingdom
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Aug 2004
- Primary completion
- 31 Jul 2006
- Completion
- 31 Jul 2006
- Last update posted
- 12 May 2009
- Registered enrollment
- 21
- Registry id
- NCT00898950
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.